The Spanish Association of Biosimilar Medicines considers that the new Reference Price Order (OPR) has not taken advantage of the opportunity to approach the sector, and that the downward price revision that this regulation undertakes, in the current economic circumstances of both increases of costs in electro-intensive industries such as high CPI, is especially burdensome.

READ MORE